These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22067790)

  • 1. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
    Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.
    Blode H; Klipping C; Richard F; Trummer D; Rohde B; Diefenbach K
    Contraception; 2012 Feb; 85(2):177-84. PubMed ID: 22067789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyaz®: an oral contraceptive fortified with folate.
    Fruzzetti F
    Womens Health (Lond); 2012 Jan; 8(1):13-9. PubMed ID: 22171769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.
    Wiesinger H; Eydeler U; Richard F; Trummer D; Blode H; Rohde B; Diefenbach K
    Clin Drug Investig; 2012 Oct; 32(10):673-84. PubMed ID: 22909145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation.
    Diefenbach K; Trummer D; Ebert F; Lissy M; Koch M; Rohde B; Blode H
    Int J Womens Health; 2013; 5():149-63. PubMed ID: 23610531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
    Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
    Rapkin RB; Creinin MD
    Expert Opin Pharmacother; 2011 Oct; 12(15):2403-10. PubMed ID: 21877996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB; Reyes-Habito CM; Lima XT; Kimball AB
    J Drugs Dermatol; 2013 Jun; 12(6):633-7. PubMed ID: 23839178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H; Schürmann R; Benda N
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
    Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
    Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive evaluation of Safyral(®) 2012.
    Nelson AL
    Womens Health (Lond); 2012 Nov; 8(6):619-33. PubMed ID: 23181528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
    Dinger J; Assmann A; Möhner S; Minh TD
    J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.